Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 6.89
AGEN's Cash to Debt is ranked lower than
61% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. AGEN: 6.89 )
Ranked among companies with meaningful Cash to Debt only.
AGEN' s 10-Year Cash to Debt Range
Min: 0.24  Med: 1.57 Max: N/A
Current: 6.89
Equity to Asset 0.39
AGEN's Equity to Asset is ranked lower than
79% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AGEN: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
AGEN' s 10-Year Equity to Asset Range
Min: -1.33  Med: -0.10 Max: 0.92
Current: 0.39
-1.33
0.92
F-Score: 4
Z-Score: -4.55
M-Score: -1.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -504.55
AGEN's Operating margin (%) is ranked lower than
72% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. AGEN: -504.55 )
Ranked among companies with meaningful Operating margin (%) only.
AGEN' s 10-Year Operating margin (%) Range
Min: -11732.38  Med: -1550.48 Max: -42.23
Current: -504.55
-11732.38
-42.23
Net-margin (%) -593.50
AGEN's Net-margin (%) is ranked lower than
75% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. AGEN: -593.50 )
Ranked among companies with meaningful Net-margin (%) only.
AGEN' s 10-Year Net-margin (%) Range
Min: -11762.54  Med: -1388.19 Max: -70.95
Current: -593.5
-11762.54
-70.95
ROE (%) -126.72
AGEN's ROE (%) is ranked lower than
85% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. AGEN: -126.72 )
Ranked among companies with meaningful ROE (%) only.
AGEN' s 10-Year ROE (%) Range
Min: -715.3  Med: -74.54 Max: -53.06
Current: -126.72
-715.3
-53.06
ROA (%) -62.08
AGEN's ROA (%) is ranked lower than
76% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. AGEN: -62.08 )
Ranked among companies with meaningful ROA (%) only.
AGEN' s 10-Year ROA (%) Range
Min: -94.08  Med: -60.78 Max: -41.12
Current: -62.08
-94.08
-41.12
ROC (Joel Greenblatt) (%) -958.21
AGEN's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. AGEN: -958.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1025.9  Med: -305.82 Max: -195.97
Current: -958.21
-1025.9
-195.97
Revenue Growth (3Y)(%) -5.00
AGEN's Revenue Growth (3Y)(%) is ranked lower than
55% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. AGEN: -5.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -54.7  Med: -5.00 Max: 100
Current: -5
-54.7
100
EBITDA Growth (3Y)(%) -7.70
AGEN's EBITDA Growth (3Y)(%) is ranked lower than
56% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. AGEN: -7.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -51  Med: -17.20 Max: 17
Current: -7.7
-51
17
EPS Growth (3Y)(%) -16.30
AGEN's EPS Growth (3Y)(%) is ranked lower than
63% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. AGEN: -16.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AGEN' s 10-Year EPS Growth (3Y)(%) Range
Min: -40  Med: -16.30 Max: 19.4
Current: -16.3
-40
19.4
» AGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AGEN Guru Trades in Q2 2014

Robert Bruce 233,515 sh (unchged)
First Eagle Investment Sold Out
George Soros Sold Out
Paul Tudor Jones 16,999 sh (-2.37%)
» More
Q3 2014

AGEN Guru Trades in Q3 2014

Robert Bruce 233,515 sh (unchged)
Paul Tudor Jones 11,197 sh (-34.13%)
» More
Q4 2014

AGEN Guru Trades in Q4 2014

Paul Tudor Jones 15,497 sh (+38.40%)
Robert Bruce 233,515 sh (unchged)
» More
Q1 2015

AGEN Guru Trades in Q1 2015

Paul Tudor Jones 29,718 sh (+91.77%)
Robert Bruce 233,515 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Agenus Inc

Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine
Disclosure: We neither own AGEN nor have any financial relationship with the company. Read more...

Ratios

vs
industry
vs
history
P/B 13.23
AGEN's P/B is ranked lower than
85% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. AGEN: 13.23 )
Ranked among companies with meaningful P/B only.
AGEN' s 10-Year P/B Range
Min: 2.5  Med: 4.65 Max: 37.35
Current: 13.23
2.5
37.35
P/S 53.80
AGEN's P/S is ranked lower than
74% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. AGEN: 53.80 )
Ranked among companies with meaningful P/S only.
AGEN' s 10-Year P/S Range
Min: 4.61  Med: 29.00 Max: 662.4
Current: 53.8
4.61
662.4
Current Ratio 4.06
AGEN's Current Ratio is ranked lower than
52% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. AGEN: 4.06 )
Ranked among companies with meaningful Current Ratio only.
AGEN' s 10-Year Current Ratio Range
Min: 0.64  Med: 4.71 Max: 42.49
Current: 4.06
0.64
42.49
Quick Ratio 4.05
AGEN's Quick Ratio is ranked lower than
51% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. AGEN: 4.05 )
Ranked among companies with meaningful Quick Ratio only.
AGEN' s 10-Year Quick Ratio Range
Min: 0.64  Med: 4.71 Max: 42.49
Current: 4.05
0.64
42.49
Days Sales Outstanding 90.60
AGEN's Days Sales Outstanding is ranked lower than
68% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. AGEN: 90.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGEN' s 10-Year Days Sales Outstanding Range
Min: 0.12  Med: 39.02 Max: 439.15
Current: 90.6
0.12
439.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 71.75
AGEN's Price/Net Cash is ranked lower than
92% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. AGEN: 71.75 )
Ranked among companies with meaningful Price/Net Cash only.
AGEN' s 10-Year Price/Net Cash Range
Min: 3.12  Med: 6.42 Max: 46.46
Current: 71.75
3.12
46.46
Price/Net Current Asset Value 43.05
AGEN's Price/Net Current Asset Value is ranked lower than
90% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. AGEN: 43.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AGEN' s 10-Year Price/Net Current Asset Value Range
Min: 3.04  Med: 6.12 Max: 25.65
Current: 43.05
3.04
25.65
Price/Tangible Book 28.70
AGEN's Price/Tangible Book is ranked lower than
91% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. AGEN: 28.70 )
Ranked among companies with meaningful Price/Tangible Book only.
AGEN' s 10-Year Price/Tangible Book Range
Min: 2.28  Med: 4.41 Max: 17.1
Current: 28.7
2.28
17.1
Price/Median PS Value 1.86
AGEN's Price/Median PS Value is ranked lower than
68% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. AGEN: 1.86 )
Ranked among companies with meaningful Price/Median PS Value only.
AGEN' s 10-Year Price/Median PS Value Range
Min: 0.2  Med: 1.19 Max: 117.31
Current: 1.86
0.2
117.31
Earnings Yield (Greenblatt) (%) -9.04
AGEN's Earnings Yield (Greenblatt) (%) is ranked lower than
63% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. AGEN: -9.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGEN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -14.5  Med: 0.00 Max: 0
Current: -9.04
-14.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AJ81.Germany,
Agenus Inc formerly known as Antigenics Inc was incorporated in 1994. The Company, along with its subsidiaries, is a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators, heat shock protein vaccines and adjuvants. It is focused on immunotherapeutic products based on core platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Its core technology portfolio consists of Heat Shock Protein Platform, and Saponin Platform. Within HSP Platform the Company is developing its Prophage Series cancer vaccines and Recombinant Series. In Prophage Series the Company has tested product candidates in Phase 3 clinical trials for the treatment of renal cell carcinoma, the common type of kidney cancer, and for metastatic melanoma, as well as in Phase 1 and Phase 2 clinical trials. In addition, the Cancer Therapy Evaluation Program of the National Cancer Institute opened patient enrollment in 2013 for a 222-patient, multi-center, randomized Phase 2 trial of Prophage Series vaccine G-200 in combination with Avastin in patients with surgically resectable recurrent glioma. HerpV, a therapeutic vaccine candidate from the Recombinant Series which contains QS-21 Stimulon, has been tested in a Phase 1 clinical trial for the treatment of genital herpes and is now in a Phase 2 trial. Within its Saponin Platform is QS-21 Stimulon adjuvant, or QS-21 Stimulon, which is used by licensees in numerous vaccines under development in trials, some as advanced as Phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer's disease, human immunodeficiency virus, and tuberculosis. The Company's business activities include product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development activities, and support of its collaborations. The Company faces intense competition from pharmaceutical companies and specialized biotechnology companies that market products or that are engaged in the development of product candidates directed at cancer, infectious diseases and degenerative disorders. Several of these companies have products that utilize similar technologies and patient-specific medicine techniques. The Company is also subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act and the Resource Conservation and Recovery Act, and other current and potential future federal, state, or local regulations.
» More Articles for AGEN

Headlines

Articles On GuruFocus.com
rusty Jan 26 2015 
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
Agenus: Grossly Undervalued GlaxoSmithKline Acquisition Target Sep 10 2012 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 2,000 Shares Sep 14 2010 

More From Other Websites
AGENUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... Jun 30 2015
Agenus Gets Billion-Dollar Valuation From Analyst Based on Cancer Drug That Doesn't Exist Jun 23 2015
Agenus to Webcast Annual Meeting of Stockholders Jun 22 2015
Agenus to Present at the 2015 JMP Securities Life Sciences Conference Jun 18 2015
AGENUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial... Jun 17 2015
Agenus Appoints C. Evan Ballantyne as Chief Financial Officer Jun 17 2015
Agenus (AGEN) Stock Higher Following Coverage Initiation Jun 11 2015
Coverage initiated on Agenus by Oppenheimer Jun 11 2015
Agenus Gains after Merck Extends Immuno-Oncology Ties - Analyst Blog Jun 04 2015
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 03 2015
Merck Extends Immuno-Oncology Collaboration with Agenus Jun 03 2015
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 01 2015
Updated Phase 2 Data of Prophage In Newly Diagnosed GBM Presented at ASCO Show Improvement in Median... Jun 01 2015
Agenus to Present at the Jefferies 2015 Healthcare Conference May 28 2015
AGENUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... May 27 2015
Agenus Announces Closing of Public Offering and Exercise in Full of Underwriters’ Option to... May 27 2015
4 stocks to watch May 27 2015
Agenus Announces Pricing of Its Public Offering of Common Stock May 21 2015
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 21 2015
Agenus Announces Proposed Public Offering of Common Stock May 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK